We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Feather Safety Razor

Download Mobile App




Image: Atomic structure of the Omicron variant spike protein (purple) bound with the human ACE2 receptor (blue) (Photo courtesy of Sriram Subramaniam)

World’s First Molecular-Level Analysis of Omicron Spike Protein to Help Develop Variant-Resistant COVID-19 Treatments

Scientists have unveiled the world’s first molecular-level analysis of the Omicron variant spike protein, revealing strong antibody evasion and binding with human cells that contribute to its increased transmissibility. More...
27 Dec 2021
Illustration

Merck and Ridgeback’s Oral Antiviral Receives US FDA EUA for Treatment of COVID-19 in Certain Adults

Merck (Kenilworth, NJ, USA) and Ridgeback Biotherapeutics (Miami, FL, USA) have been granted Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for molnupiravir, an investigational oral antiviral (MK-4482, EIDD-2801). More...
24 Dec 2021
IIR Middle East
Illustration

Pfizer’s Paxlovid Becomes First Oral COVID Antiviral Drug to Receive US FDA EUA

Pfizer Inc.’s (New York, NY, USA) PAXLOVID (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) has been authorized for emergency use by the US Food and Drug Administration (FDA) for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg [88 lbs]) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. More...
24 Dec 2021
Illustration

Blood Markers Linked to Severe COVID-19 Could Pave Way for Simple Diagnostic Tests

Scientists have identified unique “indicators” in the blood of patients with severe and fatal COVID, paving the way for simple diagnostic tests to help doctors identify who will go on to become critically ill. More...
23 Dec 2021
Image: Innovative X-Ray Imaging Showing COVID-19 Vascular Damage Could Support Routine Lab Diagnostics (Photo courtesy of M Reichardt, T Salditt)

Innovative X-Ray Imaging Showing COVID-19 Vascular Damage Could Support Routine Lab Diagnostics

An innovative X-ray imaging technique that shows COVID-19 can cause vascular damage to the heart could support pathologists with routine diagnostics. More...
23 Dec 2021
Illustration

Study Reveals New Imaging Findings in Patients with Breakthrough COVID-19 Infections

A new study has found that the majority of patients with breakthrough COVID-19 illness had absent or mild imaging findings and a benign clinical course. More...
17 Dec 2021
Illustration

Regeneron’s Next-Gen COVID-19 Monoclonal Antibodies Active Against All Known VOCs, Including Omicron and Delta

Regeneron Pharmaceuticals, Inc.’s (Tarrytown, NY, USA) next generation monoclonal antibodies are active against all known SARS-CoV-2 variants of concern, including both Omicron and Delta. More...
17 Dec 2021
Copyright © 2000-2022 Globetech Media. All rights reserved.